Search
TEVA · Company research

Teva Pharmaceutical Industries Limited (TEVA): Stock News & Events

Recent company-linked news records available in the database.

Main stock researchCompare stocks
RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

26records availableHealthcare

Stock News & Events data

Database-backed records only

26 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsightThe global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.View source ↗GlobeNewswire Inc.Oct 19, 2026bullish11
Global Brain Health Supplements Market Size, Share, Trends and Forecast, 2026-2035 | Market to Reach USD 35.41 Billion as Natural Products and E-commerce Drive 11% CAGRThe global brain health supplements market is projected to grow from USD 12.47 billion in 2025 to USD 35.41 billion by 2035, driven by increasing consumer awareness of cognitive wellness, demand for natural ingredients, and e-commerce expansion. North America leads with 43.1% market share, while memory enhancement remains the top application. Key growth factors include aging populations, younger consumers seeking cognitive support, and clinical validation of natural ingredients like Bacopa monnieri and Ginkgo Biloba.View source ↗GlobeNewswire Inc.Oct 16, 2026bullish11
Global Brain Health Supplements Market Size, Share, Trends and Forecast, 2026-2035 | Market to Reach USD 35.41 Billion as Natural Products and E-commerce Drive 11% CAGRThe global brain health supplements market is projected to grow from USD 12.47 billion in 2025 to USD 35.41 billion by 2035, driven by increasing consumer awareness of cognitive wellness, demand for natural ingredients, and e-commerce expansion. North America leads with 43.1% market share, while memory enhancement remains the top application. Key growth factors include aging populations, younger consumers seeking cognitive support, and clinical validation of natural ingredients like Bacopa monnieri and Ginkgo Biloba.View source ↗GlobeNewswire Inc.Oct 16, 2026bullish11
Barclays keeps Buy rating for Teva stock at USD 42.00 - ad-hoc-news.deBarclays keeps Buy rating for Teva stock at USD 42.00 ad-hoc-news.deView source ↗ad-hoc-news.deOct 14, 2026neutral00.6
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock DownJohnson & Johnson reported Q3 2026 adjusted earnings of $2.59 per share, beating estimates, but sales of $25.4 billion missed expectations. Innovative Medicine sales grew 7.7% driven by Tremfya and newer therapies, while Stelara faced significant biosimilar competition. MedTech underperformed with a 2.5% increase missing estimates. J&J raised 2026 guidance but shares declined 2% in pre-market trading due to weaker-than-expected MedTech results.View source ↗Zacks Investment ResearchOct 13, 2026bullish0.751
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock DownJohnson & Johnson reported Q3 2026 adjusted earnings of $2.59 per share, beating estimates, but sales of $25.4 billion missed expectations. Innovative Medicine sales grew 7.7% driven by Tremfya and newer therapies, while Stelara faced significant biosimilar competition. MedTech underperformed with a 2.5% increase missing estimates. J&J raised 2026 guidance but shares declined 2% in pre-market trading due to weaker-than-expected MedTech results.View source ↗Zacks Investment ResearchOct 13, 2026bullish0.751
Teva leaders will discuss medicines in development and the company's potential over five years. - Stock TitanTeva leaders will discuss medicines in development and the company's potential over five years. Stock TitanView source ↗Stock TitanOct 12, 2026neutral00.6
Teva to Host R&D Day on Wednesday, November 11 in New York CityTeva Pharmaceutical Industries announced it will host an R&D Day on November 11, 2026, in New York to discuss its R&D pipeline and transformation strategy into an innovative biopharma company. The company also announced FDA approval of WELTRUZA™ (olanzapine), the first and only once-monthly subcutaneous injectable olanzapine for adults with schizophrenia.View source ↗GlobeNewswire Inc.Oct 12, 2026bullish11
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at JPMorgan Chase & Co. - MarketBeatTeva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at JPMorgan Chase & Co. MarketBeatView source ↗MarketBeatOct 12, 2026neutral00.6
TEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament - Yahoo FinanceTEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament Yahoo FinanceView source ↗Yahoo FinanceOct 12, 2026neutral00.6
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in SchizophreniaTeva Pharmaceutical Industries announced FDA approval of Weltruza (olanzapine) extended-release injectable suspension, the first once-monthly subcutaneous formulation for treating schizophrenia in adults. The drug will launch in the U.S. in coming weeks with three dosage strengths and requires no loading doses or post-injection monitoring. This approval expands Teva's schizophrenia portfolio alongside its existing Uzedy product, which generated $140 million in sales in the first half of 2026.View source ↗Zacks Investment ResearchOct 12, 2026bullish0.51
JPMorgan raises Teva stock price target to $50 on Weltruza approval - Investing.comJPMorgan raises Teva stock price target to $50 on Weltruza approval Investing.comView source ↗Investing.comOct 12, 2026neutral00.6
Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval - Investor's Business DailyTeva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval Investor's Business DailyView source ↗Investor's Business DailyOct 9, 2026neutral00.6
Teva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment - StocktwitsTeva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment StocktwitsView source ↗StocktwitsOct 9, 2026neutral00.6
Stocks making the biggest moves midday: T-Mobile, Verizon, AT&T, Crown Castle, Teva & more - CNBCStocks making the biggest moves midday: T-Mobile, Verizon, AT&T, Crown Castle, Teva & more CNBCView source ↗CNBCOct 9, 2026neutral00.6
Teva shares climb as biosimilar approval and fresh bullish coverage support momentum - Quiver QuantitativeTeva shares climb as biosimilar approval and fresh bullish coverage support momentum Quiver QuantitativeView source ↗Quiver QuantitativeOct 9, 2026neutral00.6
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?Johnson & Johnson will report Q3 2026 results on October 13 with consensus estimates for $25.37 billion in sales and $2.66 EPS. The company's Innovative Medicine segment is expected to drive growth through key drugs like Darzalex and new launches, but faces headwinds from Stelara biosimilar competition and upcoming patent expirations. Despite valuation concerns, analysts recommend staying invested given J&J's diversified business model, consistent growth trajectory, and pipeline strength.View source ↗Zacks Investment ResearchOct 9, 2026bullish0.3331
Teva stock hits 52-week high at 40.84 USD - Investing.comTeva stock hits 52-week high at 40.84 USD Investing.comView source ↗Investing.comOct 9, 2026neutral00.6
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia - Teva PharmaceuticalsTeva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia Teva PharmaceuticalsView source ↗Teva PharmaceuticalsOct 9, 2026neutral00.6
TEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot - Yahoo FinanceTEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot Yahoo FinanceView source ↗Yahoo FinanceOct 9, 2026neutral00.6
Teva (TEVA) Stock Fair Value Rises As Analysts Back CNS Transformation - Yahoo FinanceTeva (TEVA) Stock Fair Value Rises As Analysts Back CNS Transformation Yahoo FinanceView source ↗Yahoo FinanceOct 9, 2026neutral00.6
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price - Simply Wall StreetTeva Pharmaceutical Industries (NYSE:TEVA) Stock Price Simply Wall StreetView source ↗Simply Wall StreetOct 8, 2026neutral00.6
Teva seeks to keep Israel ties from jury, cites Gaza war - ReutersTeva seeks to keep Israel ties from jury, cites Gaza war ReutersView source ↗ReutersAug 6, 2026neutral00.6
Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations - Barron'sTeva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations Barron'sView source ↗Barron'sJul 29, 2026neutral00.6
Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right. - The Motley FoolWall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right. The Motley FoolView source ↗The Motley FoolJul 26, 2026neutral00.6
Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right. - The Motley FoolWall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right. The Motley FoolView source ↗The Motley FoolMay 14, 2026neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.